EMA (EU)
EVENT
Workshop on advancing proof-of-concept data in paediatric oncology drug development
Published: 9/21/2026Detected: 9/12/2026
Summary preview
Workshop to inform the development of a future EMA reflection paper on what constitutes adequate proof-of-concept evidence for anti-cancer medicinal products in paediatric patients.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountoncology
pediatrics
clinical
safety
#EMA
#paediatric oncology
#proof-of-concept
#reflection paper
#public consultation
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026